Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Short Interest Up 68.7% in July

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) saw a significant growth in short interest in July. As of July 31st, there was short interest totaling 8,827 shares, a growth of 68.7% from the July 15th total of 5,232 shares. Based on an average trading volume of 4,750 shares, the short-interest ratio is presently 1.9 days. Currently, 0.3% of the company’s stock are sold short.

Invesco Biotechnology & Genome ETF Stock Up 1.0%

PBE traded up $0.98 during trading on Monday, hitting $94.72. The company had a trading volume of 7,043 shares, compared to its average volume of 12,884. The company has a market capitalization of $298.37 million, a PE ratio of 20.44 and a beta of 0.70. Invesco Biotechnology & Genome ETF has a one year low of $67.41 and a one year high of $95.01. The firm’s 50-day moving average price is $89.71 and its 200 day moving average price is $83.84.

Institutional Trading of Invesco Biotechnology & Genome ETF

A number of institutional investors have recently modified their holdings of PBE. Colonial Trust Advisors bought a new position in shares of Invesco Biotechnology & Genome ETF during the fourth quarter worth about $25,000. Compass Financial Management LLC bought a new stake in Invesco Biotechnology & Genome ETF in the 2nd quarter valued at approximately $27,000. Fifth Third Bancorp acquired a new position in Invesco Biotechnology & Genome ETF during the 1st quarter worth approximately $30,000. Comerica Bank boosted its position in Invesco Biotechnology & Genome ETF by 86.2% during the 4th quarter. Comerica Bank now owns 378 shares of the company’s stock worth $31,000 after acquiring an additional 175 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in shares of Invesco Biotechnology & Genome ETF by 74.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock worth $40,000 after acquiring an additional 245 shares in the last quarter.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.